Although p300/CBP inhibitors have demonstrated selective activity against AML patients with FLT3-ITD mutation, their efficacy as monotherapy is limited, necessitating further investigation into the concurrent inhibition of p300/CBP and FLT3. This evidence concerns the gene EP300 and acute myeloid leukemia.